Schedule 13G ownership disclosure

Inhibikase Therapeutics Inc

Common Stock, $0.001 par value · CUSIP: 45719W205

Event date: 2025-12-23

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Trails Edge Capital Partners, LP

    Shares: 6,145,198.00 · Class: 5.1%

  • Trails Edge Biotechnology Master Fund, LP

    Shares: 6,145,198.00 · Class: 5.1%

  • Ortav Yehudai

    Shares: 6,145,198.00 · Class: 5.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001493152-25-029834
Form type
SCHEDULE 13G
Filer
Inhibikase Therapeutics, Inc.
CIK
CIK 1750149
Filed
Dec 31, 2025
Reporting period
Dec 23, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub